Press Releases GRI BIOPAR

Equities

GRI

US3622AW1069

Delayed Nasdaq Other stock markets 12:52:01 2024-07-03 pm EDT			5-day change	1st Jan Change
1.6 ^USD	-2.44%		-12.57%	-76.12%

Jun. 26	Wall Street Set to Open Marginally Lower Ahead of New Home Sales, GDP Figures	MT
Jun. 26	Top Premarket Decliners	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine	Jul. 02	AQ
GRI Bio to Present at the 8th Annual IPF Summit	Jul. 01	AQ
GRI Bio Announces Closing of $4.0 Million Public Offering	Jun. 28	AQ
GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators	Jun. 27	AQ
GRI Bio Announces Pricing of $4 Million Public Offering	Jun. 27	AQ
GRI Bio Announces Reverse Stock Split	Jun. 14	AQ
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference	Jun. 11	AQ
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs	May. 22	AQ
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)	May. 21	AQ
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)	May. 20	AQ
GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase	May. 14	AQ
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update	May. 13	AQ
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity	Apr. 29	AQ
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar	Apr. 25	AQ
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent	Apr. 16	AQ
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference	Apr. 08	AQ
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update	Apr. 01	AQ
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference	Mar. 28	AQ
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators	Mar. 14	AQ
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom	Mar. 04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases GRI BIOPAR

Equities

GRI

US3622AW1069

Press Releases

Filters